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microRNAHere, we found that members of themicroRNA-29 family (miR-29a/b/c; ‘‘miR-29s’’) were signiﬁcantly
reduced in clear cell renal cell carcinoma (ccRCC) tissues, suggesting that they functioned as tumour
suppressors. Restoration of all mature members of the miR-29 family inhibited cancer cell
proliferation, migration and invasion. LOXL2 was a direct target gene of miR-29s, as shown by
genome-wide gene expression analysis and luciferase reporter assay. Overexpressed LOXL2 was
conﬁrmed in ccRCC clinical specimens, and silencing of LOXL2 inhibited cancer cell migration and
invasion in ccRCC cell lines. Our data demonstrated that the miR-29s-LOXL2 axis contributed to
cancer cell migration and invasion in ccRCC.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Renal cell carcinoma (RCC) is a disease in which cells undergo
oncogenic transformation in the kidney tubules. Clear cell RCC
(ccRCC) is the most common subtype (approximately 80%) of RCC
[1]. The ﬁve-year survival rate of advanced stage RCC is poor
(5–10%) due to recurrence or distant metastasis [1]. At diagnosis,
about 30% of RCCs have already metastasized [2]. Recently,
anti-angiogenic multi-tyrosine kinase inhibitors have been devel-
oped and have been used as ﬁrst and second line treatments for
RCC. However, these treatments extend progression-free survival
only slightly, and relapse and metastasis eventually develop in
most patients [3]. The molecular mechanisms of RCC recurrence,
metastasis and drug resistance are not yet fully understood.
Therefore, analysis of the molecular mechanisms underlying RCC
development and progression and studies of novel oncogenicpathways based on current genome-based approaches could sig-
niﬁcantly improve diagnosis, therapy, and prevention of the
disease.
The human genome sequence era has brought a ﬂood of new
information. For example, it has been found that vast numbers of
non-coding RNAs (ncRNAs) are transcribed in human cells. The dis-
covery of ncRNAs has provided conceptual breakthrough in the
study of cancer. MicroRNAs (miRNAs) are endogenous small
ncRNA molecules (19–22 bases in length) that regulate
protein-coding gene expression by repressing translation or cleav-
ing RNA transcripts in a sequence-speciﬁc manner [4]. A substan-
tial amount of evidence suggests that miRNAs are aberrantly
expressed in many human cancers and play signiﬁcant roles in
human oncogenesis and metastasis [5]. In cancer cells, it is
believed that normal regulatory mechanisms involving messenger
RNA (mRNAs)–miRNA networks can be disrupted by the aberrant
expression of miRNAs. Therefore, identiﬁcation of aberrantly
expressed miRNAs is an important ﬁrst step toward elucidating
the details of miRNA-mediated oncogenic pathways in cancer cells.
Our recent studies demonstrated that the microRNA-29 family
(miR-29a, miR-29b and miR-29c; ‘‘miR-29s’’) was signiﬁcantly
reduced in several miRNA expression signatures of human cancers,
including RCC [6–8]. Moreover, gain-of-function assays showed
that restoration of these miRNAs inhibited cancer cell migration
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ﬁndings suggest thatmiR-29s act as tumor suppressors. In contrast,
upregulation of miR-29s was reported in breast cancer, colon can-
cer and acute myeloid leukemia [9–11]. The functional signiﬁcance
of miR-29s in ccRCC has been unclear. Furthermore, miRNA regula-
tion of RNA networks is varied, depending on the particular type of
cancer cell. Thus, identiﬁcation of miR-29 modulation of cancer
networks is needed to elucidate molecular mechanisms of ccRCC
initiation, progression and metastasis.
The aim of the current study was to investigate the functional
roles of miR-29s in ccRCC cells and determine how these miRNAs
might regulate novel cancer pathways. Our data demonstrated that
restoration of maturemiR-29a,miR-29b andmiR-29c inhibited can-
cer cell migration and invasion. Moreover, gene expression data
and in silico database analysis showed that the lysyl oxidase-like
2 (LOXL2) gene was a direct target of miR-29 regulation. Silencing
of the LOXL2 gene signiﬁcantly inhibited the migration and inva-
sion of cancer cells. The discovery of pathways regulated by the
tumour-suppressive miR-29-LOXL2 axis provides important
insights into the potential mechanisms of ccRCC oncogenesis and
suggests novel therapeutic strategies for the treatment of ccRCC.
2. Materials and methods
2.1. Clinical renal specimens
A total of 24 pairs of ccRCC specimens and adjacent
non-cancerous specimens were collected from patients who had
undergone radical nephrectomies at Kagoshima University
Hospital (Kagoshima, Japan). Samples were staged according to
the General Rule for Clinical and Pathological Studies on Renal
Cell Carcinoma based on the American Joint Committee onTable 1
Characteristics of ccRCC clinical specimens.
n (%)
Male 18 (75.0)
Female 6 (25.0)
Clinical N stage
cN0 22 (91.6)
cN1 1 (4.2)
cN2 0 (0.0)
cNX 1 (4.2)
Pathological tumour stage
pT1a 16 (66.7)
pT1b 4 (16.7)
pT2 0 (0.0)
pT3a 2 (8.3)
pT3b 2 (8.3)
pT3c 0 (0.0)
pT4 0 (0.0)
Grade
G1 1 (4.2)
G2 18 (75.0)
G3 4 (16.7)
Unknown 1 (4.2)
Microvascular invasion
Yes 9 (37.7)
No 15 (62.3)
Metastasis
Yes 2 (8.3)
No 21 (13.1)
Unknown 1 (8.2)
Recurrence
Yes 0 (0.0)
No 16 (66.7)
Unknown 8 (33.3)Cancer (AJCC)-UICC TNM classiﬁcation [12,13]. The patients’ back-
grounds and clinico-pathological characteristics are summarized in
Table 1. Prior written informed consent and approval were pro-
vided by each patient.
2.2. Cell culture and RNA extraction
786-O and A498, human RCC cell lines that were obtained from
the American Type Culture Collection (Manassas, VA, USA), were
maintained in RPMI-1640 medium supplemented with 10% fetal
bovine serum in a humidiﬁed atmosphere of 5% CO2 and 95% air
at 37 C.
Total RNA was isolated using the TRIzol regimen (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s protocol. RNA
quality was conﬁrmed using an Agilent 2100 Bioanalyzer (Agilent
Technologies, Santa Clara, CA, USA).
2.3. Quantitative real-time RT-PCR
The procedure for PCR quantiﬁcation was described previously
[6,14]. TaqMan probes and primers for LOXL2 (P/N:
Hs00158757_m1; Applied Biosystems, Foster City, CA, USA) and
for GUSB (the internal control; P/N: Hs99999908_m1; Applied
Biosystems) were assay-on-demand gene expression products.
The expression levels of miR-29a (Assay ID: 002112), miR-29b
(Assay ID: 000413) and miR-29c (Assay ID: 000587) were analyzed
by TaqMan quantitative real-time PCR (TaqMan MicroRNA Assay;
Applied Biosystems) and normalized to the expression of U6
(Assay ID: 001973). All reactions were performed in triplicate,
and each assay included negative control reactions that lacked
cDNA.
2.4. Transfections with mature miRNA, small interfering RNA (si-RNA)
and LOXL2 expression vector
The following mature miRNA species were used in this study:
mirVana miRNA mimic for hsa-miR-29a-3p (product ID:
MC12499; Applied Biosystems), hsa-miR-29b-3p (product ID:
MC10103), and hsa-miR-29c-3p (product ID: MC10518). The fol-
lowing si-RNAs were used: Stealth Select RNAi si-RNA, si-LOXL2
(P/N: si-LOXL2-1: HSS106124, si-LOXL2-2: HSS180848;
Invitrogen), and negative control miRNA/siRNA (P/N: AM17111;
Applied Biosystems). Transfection methods were described as pre-
viously [6,15].
For LOXL2 rescue experiments, 2 lg of pCMV6-XL5-plasmid
vector containing LOXL2 (SC118675; OriGene, Rockville, MD,
USA) was transfected 24 h before miRNAs transfection by using
Lipofectamine 2000 transfection reagent (Life Technologies,
Carlsbad, CA, USA).
2.5. Cell proliferation, migration and invasion assays
786-O and A498 cells were transfected with 10 nM miRNAs or
si-RNA by reverse transfection. Cell proliferation, migration, and
invasion assays were performed as described previously [6,17].
2.6. Western blotting
Cells were harvested 96 h after transfection, and lysates were
prepared. Fifty lg protein lysates were separated on
Mini-PROTEAN TGX gels (Bio-Rad, Hercules, CA, USA) and trans-
ferred to PVDF membranes. Immunoblotting was performed with
rabbit anti-LOXL2 antibodies (1:1000; ab96233; Abcam,
Cambridge, UK). Anti-GAPDH antibodies (1:1000; ab8245,
Abcam) were used as an internal loading control.
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expression data
To identify miR-29 target genes, we used in silico analysis
and genome-wide gene expression analysis. First, we screened
genes using TargetScan Release 6.2 (http://www.targetscan.org/).
To identify upregulated genes in ccRCC clinical specimens, we
analyzed publicly available gene expression proﬁles in the GEO
database (accession number: GSE22541, GSE36895). Also, we
performed gene expression analysis using miR-29a-transfected
786-O and A498 cells. Oligo-microarray Human 60K
(Agilent) was used for gene expression studies. Microarray
procedures and data mining methods were described previously
[6].
2.8. Plasmid construction and dual-luciferase reporter assay
Partial wild-type (WT) sequences of the LOXL2 30-untranslated
region (UTR) or those with deleted miR-29 target sites (positions
555–561 and 757–763 of the LOXL2 30-UTR) were inserted between
the XhoI–PmeI restriction sites in the 30-UTR of the hRluc gene in
the psiCHECK-2 vector (C8021; Promega, Madison, WI, USA). The
protocol for vector construction was described previously [6,16].
A498 cells were transfected with 50 ng of the vector and 10 nM
miR-29a, miR-29b and miR-29c using Lipofectamine 2000
(Invitrogen). The activities of ﬁreﬂy and Renilla luciferases in cell
lysates were determined with a dual-luciferase assay system
(E1910; Promega). Normalized data were calculated as the ratio
of Renilla/ﬁreﬂy luciferase activities.Fig. 1. Expression levels of miR-29s in RCC clinical specimens and cell lines. (A) Express
(786-O and A498) were measured by qRT-PCR. U6 was used for normalization. (B) Co
determined in RCC clinical specimens.2.9. Immunohistochemistry
Tissue specimens were immunostained following previously
described protocols [17]. Primary rabbit polyclonal antibodies
against LOXL2 (Abcam) were diluted 1:1000.
2.10. Statistical analysis
The relationships between two groups and the numerical values
obtained by real-time RT-PCR were analyzed using the paired
t-test. The relationships among three variables and numerical val-
ues were analyzed using the Bonferroni-adjusted Mann–Whitney
U test. All analyses were performed using Expert StatView software
(version 4, SAS Institute Inc., Cary, NC, USA).
3. Results
3.1. Expression levels of miR-29a, miR-29b and miR-29c in ccRCC
clinical specimens and cell lines
The expression levels of miR-29a, miR-29b and miR-29c were
signiﬁcantly lower in ccRCC tissues than in corresponding
non-cancerous kidney tissues (P = 0.0002, P = 0.0003, and
P < 0.0001, respectively; Fig. 1A). In 786-O and A498 cells, levels
were signiﬁcantly lower than in normal kidney tissues (Fig. 1A).
Spearman’s rank test showed a positive correlation between the
expression of miR-29a and that of miR-29b (R = 0.836 and
P < 0.0001, Fig. 1B). The expression of miR-29a was positively cor-
related with that of miR-29c (R = 0.878 and P < 0.0001, Fig. 1B).ion levels of miR-29a, miR-29b and miR-29c in RCC clinical specimens and cell lines
rrelations between miR-29a-miR-29b, miR-29a-miR-29c and miR-29b-miR-29c were
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that of miR-29c (R = 0.744 and P < 0.0001, Fig. 1B).
We evaluated the expression levels of miR-29a, miR-29b and
miR-29c in each miR-29s transfectant cells. We conﬁrmed overex-
pression of miR-29a in miR-29a transfectant cells.
The change of the expression levels of miR-29b and miR-29c
were not detected in miR-29a transfectant cells (Supplemental
Fig. 1A). We conﬁrmed similar results in miR-29b and miR-29c
transfectant cells (Supplemental Fig. 1B and C). In this
gain-of-function assays, restoration of miR-29s may be overex-
pressed in cancer cells compared with normal kidney tissues
(Supplemental Fig. 1).
3.2. Effects of restoring miR-29a, miR-29b and miR-29c on cell
proliferation, migration and invasion activities in ccRCC cell lines
To investigate the functional effects of all members of the
mature miR-29 family (miR-29a, miR-29b and miR-29c), we per-
formed gain-of-function studies using mature miRNA transfection
of 786-O and A498 cell lines.Fig. 2. Effect of miR-29 transfection on RCC cell lines. (A) Cell proliferation 72 h after tran
activity 48 h after transfection with 10 nM miR-29s was determined with the migratio
determined with the invasion assay. **P < 0.0001; *P < 0.0005. All experiments were perfThe XTT assay demonstrated that cell proliferation was inhib-
ited in miR-29 transfectants in comparison with the mock or
miR-control transfectant cells (Fig. 2A).
The migration assay demonstrated that cell migration
activity was signiﬁcantly inhibited in miR-29 transfectants in
comparison with the mock or miR-control transfectant cells
(Fig. 2B).
The Matrigel invasion assay demonstrated that cell invasion
activity was signiﬁcantly inhibited in miR-29 transfectants
in comparison with the mock or miR-control transfectant cells
(Fig. 2C).
3.3. Identiﬁcation of putative candidate target genes of miR-29s in
ccRCC cells
To gain further insight into the genes affected by miR-29s, we
used in silico analysis and genome-wide gene expression analysis.
First, we screened miR-29a-targeted genes using the TargetScan
database and identiﬁed 2627 genes. Next, we pared down the
list of genes based on two kinds of gene expression data:sfection with 10 nMmiR-29s was determined with the XTT assay. (B) Cell migration
n assay. (C) Cell invasion activity 48 h after transfection with 10 nM miR-29s was
ormed in triplicate.
Table 2
Putative candidate of target genes regulated by miR-29a.
Entrez
gene ID
Gene
symbol
Gene name Location Expression in miR-29a
transfectant (log2 ratio)
GEO expression
data (GSE36895,
GSE22541)
(log2 ratio)
Conserved
sites
Poorly
conserved
sites
786-O A498 Average
4017 LOXL2 Lysyl oxidase-like 2 8p21.3 2.87 3.27 3.07 2.77 1 1
57761 TRIB3 Tribbles pseudokinase 3 20p13–p12.2 3.84 1.95 2.90 2.43 0 1
6678 SPARC Secreted protein, acidic, cysteine-rich
(osteonectin)
5q31.3–q32 2.51 2.10 2.31 1.00 2 0
57561 ARRDC3 Arrestin domain containing 3 5q14.3 2.59 1.43 2.01 0.77 1 1
23476 BRD4 Bromodomain containing 4 19p13.1 1.95 2.00 1.97 0.34 0 1
11167 FSTL1 Follistatin-like 1 3q13.33 1.40 2.50 1.95 1.19 1 1
871 SERPINH1 Serpin peptidase inhibitor, clade H (heat
shock protein 47), member 1, (collagen
binding protein 1)
11q13.5 1.49 2.22 1.86 1.78 1 0
55920 RCC2 Regulator of chromosome condensation 2 1p36.13 1.93 1.71 1.82 0.63 1 0
114904 C1QTNF6 C1q and tumor necrosis factor related protein
6
22q13.1 2.06 1.44 1.75 0.79 2 2
51092 SIDT2 SID1 transmembrane family, member 2 11q23.3 1.98 1.44 1.71 0.32 1 0
79026 AHNAK AHNAK nucleoprotein 11q12.2 2.05 1.34 1.70 1.02 0 1
7106 TSPAN4 Tetraspanin 4 11p15.5 1.60 1.78 1.69 0.63 1 0
1282 COL4A1 Collagen, type IV, alpha 1 13q34 1.71 1.66 1.68 1.30 2 0
30846 EHD2 EH-domain containing 2 19q13.3 1.84 1.47 1.66 3.20 1 0
10058 ABCB6 ATP-binding cassette, sub-family B (MDR/
TAP), member 6 (Langereis blood group)
2q36 1.53 1.77 1.65 1.12 1 0
284119 PTRF Polymerase I and transcript release factor 17q21.2 1.49 1.80 1.64 1.29 1 0
9514 GAL3ST1 Galactose-3-O-sulfotransferase 1 22q12.2 1.66 1.62 1.64 2.79 0 1
56951 C5orf15 Chromosome 5 open reading frame 15 5q31.1 1.41 1.84 1.63 0.28 1 0
3915 LAMC1 Laminin, gamma 1 (formerly LAMB2) 1q31 1.71 1.44 1.58 1.03 1 0
5376 PMP22 Peripheral myelin protein 22 17p12 1.61 1.52 1.56 1.66 1 0
202 AIM1 Absent in melanoma 1 6q21 1.42 1.66 1.54 0.35 1 0
1284 COL4A2 Collagen, type IV, alpha 2 13q34 1.30 1.77 1.53 1.47 1 0
7106 TSPAN4 Tetraspanin 4 11p15.5 1.60 1.44 1.52 0.63 1 0
80727 TTYH3 Tweety family member 3 7p22 1.76 1.24 1.50 1.10 0 1
3688 ITGB1 Integrin, beta 1 (ﬁbronectin receptor, beta
polypeptide, antigen CD29 includes MDF2,
MSK12)
10p11.2 1.72 1.27 1.49 0.49 1 0
116441 TM4SF18 Transmembrane 4 L six family member 18 3q25.1 1.55 1.38 1.46 0.75 0 1
6882 TAF11 TAF11 RNA polymerase II, TATA box binding
protein (TBP)-associated factor, 28kDa
6p21.31 1.59 1.31 1.45 0.27 1 1
51133 KCTD3 Potassium channel tetramerization domain
containing 3
1q41 1.28 1.56 1.42 0.70 1 0
80381 CD276 CD276 molecule 15q23–q24 1.51 1.31 1.41 0.85 1 0
7132 TNFRSF1A Tumor necrosis factor receptor superfamily,
member 1A
12p13.2 1.74 1.07 1.41 0.89 1 0
5538 PPT1 Palmitoyl-protein thioesterase 1 1p32 1.52 1.15 1.33 0.52 0 1
840 CASP7 Caspase 7, apoptosis-related cysteine
peptidase
10q25 1.52 1.09 1.31 0.36 1 0
83742 MARVELD1 MARVEL domain containing 1 10q24.2 1.30 1.31 1.30 1.02 0 1
90861 HN1L Hematological and neurological expressed 1-
like
16p13.3 1.43 1.10 1.26 0.99 0 2
6996 TDG Thymine-DNA glycosylase 12q24.1 1.23 1.29 1.26 0.41 2 1
7168 TPM1 Tropomyosin 1 (alpha) 15q22.1 1.15 1.27 1.21 0.59 1 0
6455 SH3GL1 SH3-domain GRB2-like 1 19p13.3 1.21 1.14 1.18 0.94 0 1
64175 LEPRE1 Leucine proline-enriched proteoglycan
(leprecan) 1
1p34.1 1.18 1.11 1.14 0.82 0 1
7168 TPM1 Tropomyosin 1 (alpha) 15q22.1 1.15 1.13 1.14 0.59 1 0
81605 URM1 Ubiquitin related modiﬁer 1 9q34.11 1.01 1.12 1.07 0.25 1 0
23468 CBX5 Chromobox homolog 5 12q13.13 1.02 1.08 1.05 0.73 2 3
2140 R. Nishikawa et al. / FEBS Letters 589 (2015) 2136–2145(1) upregulated genes determined by the gene expression data set
of RCC clinical specimens in the GEO (Gene Expression Omnibus)
database (accession numbers: GSE36895, GSE22541); (2) down-
regulated genes (log2 ratio <1.0) following miR-29a transfection
of 786-O and A498 cells. The expression data of miR-29s trans-
fected RCC cell lines were deposited in the GEO database (accession
number: GSE66498).
From this selection, 41 candidate genes were identiﬁed as tar-
gets of the miR-29 family (Table 2). Among these candidates, we
focused on the LOXL2 gene and examined LOXL2 function and char-
acteristics in further analyses.3.4. LOXL2 was a direct target of miR-29 regulation in ccRCC cells
We performed quantitative real-time RT-PCR analysis and
Western blotting assessment of 786-O and A498 cells to investi-
gate whether LOXL2 gene expression and LOXL2 protein expression
were reduced by restoration of miR-29s. The mRNA and protein
expression levels of LOXL2/LOXL2 were signiﬁcantly repressed in
miR-29s transfectants in comparison with mock or miR-control
transfectants (Fig. 3A and B).
We performed luciferase reporter assays of A498 to determine
whether LOXL2 mRNA had target sites for miR-29s. The
Fig. 3. Direct regulation of LOXL2 by miR-29s. (A) The mRNA expression levels 72 h after transfection with miR-29s in RCC cell lines were measured by qRT-PCR. GUSB was
used for normalization. (B) LOXL2 protein expression levels 96 h after transfection withmiR-29s. GAPDH was used for a loading control. (C) ThemiR-29s binding site in the 30-
UTR of LOXL2mRNA. Luciferase reporter assays were performed using vectors that included (WT) or lacked (DEL) the WT sequences of the putativemiR-29s target site. Renilla
luciferase assays were normalized to ﬁreﬂy luciferase values. **P < 0.0001. All experiments were performed in triplicate.
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sites existed in the 30-UTR of LOXL2 (positions 555–561 and
757–763, Fig. 3C). We used vectors encoding either the partial
WT sequence of the 30-UTR of LOXL2 mRNA, including the predicted
miR-29s target sites, or ‘deletion’ vectors, that is, those lacking
the miR-29s target sites. We found that the luminescence intensity
was signiﬁcantly reduced by transfection with miR-29s and two
vectors carrying the WT 30-UTR of LOXL2 (positions 555–561 and
757–763), whereas transfection with deletion vectors (where
nucleotides at positions 555–561 or 757–763 had been removed)
blocked the decrease in luminescence (P < 0.0001, Fig. 3C). These
data suggested that miR-29s bound directly to two speciﬁc
binding sites in the 30-UTR of LOXL2 mRNA.
3.5. Effects of downregulating LOXL2 on cell proliferation, migration
and invasion in ccRCC cell lines
To investigate the functional role of LOXL2 in ccRCC cells, we
performed loss-of-function studies using two si-LOXL2 transfectant
cells (si-LOXL2-1 and si-LOXL2-2). First, we evaluated the knock-
down efﬁciency of si-LOXL2 treatments in 786-O and A498 cells.
Quantitative real-time RT-PCR and Western blotting indicated that
the siRNA effectively downregulated LOXL2/LOXL2 expression in
both cell lines (Fig. 4A and B).
The XTT assay demonstrated that cell proliferation was not
inhibited in all si-LOXL2 transfectant cells in comparison with the
mock or miR-control transfectant cells (Fig. 4C). In contrast, the
migration assay demonstrated that cell migration activity was sig-
niﬁcantly inhibited in all si-LOXL2 transfectant cells in comparison
with the mock or negative control transfectants (Fig. 4D). The
Matrigel invasion assay demonstrated that cell invasion activitywas signiﬁcantly inhibited in all si-LOXL2 transfectant cells in
comparison with the mock or negative control transfectants
(Fig. 4E).
3.6. Effects of co-transfection of LOXL2 and miR-29s in RCC cell lines
To conﬁrm the miR-29s-LOXL2 mediating anti-tumour effect in
RCC cells, we co-expressed LOXL2 and miR-29s in RCC cells.
LOXL2 rescue study indicated that cell proliferation, migration
and invasion properties were rescued by LOXL2 transfectants as
compared with cells restored miR-29a, miR-29b and miR-29c only
(Fig. 2 and Supplemental Fig. 2). These data suggested that role
of LOXL2 protein was modulated by miR-29s and had effects on
proliferation, migration and invasion in RCC cells.
3.7. LOXL2 expression in RCC specimens
We evaluated the mRNA expression levels of LOXL2 in RCC clin-
ical specimens. The expression of LOXL2 was signiﬁcantly upregu-
lated in cancer tissues compared with normal tissues (P = 0.0012),
as demonstrated by RT-PCR (Fig. 5A). Spearman’s rank test showed
a negative correlation between the expression of miR-29s and
LOXL2 (Fig. 5B). We also determined the expression levels of
LOXL2 in RCC specimens by immunohistochemical staining.
LOXL2 was strongly expressed in several cancer lesions, whereas
no or low expression was observed in normal regions (Fig. 6).
There was no signiﬁcant correlation between miR-29s or LOXL2
expression and various tested clinicopathological parameters of
RCC specimens. The large number of cohort study will be necessary
to investigate the expression status of miR-29s or LOXL2 and RCC
clinical features.
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The genomic structure of the human miR-29 family is unique.
The miR-29s include three members, miR-29a, miR-29b and
miR-29c. miR-29b includes two members, miR-29b-1 and
miR-29b-2. These miRNAs form clusters at two genomic loci:
miR-29b-1 and miR-29a in 7q32 and miR-29b-2 and miR-29c in
1q32 [18,19]. Studies of miRNA expression signatures (including
that from our laboratory [14]) showed that certain miR-29s were
aberrantly expressed in several types of human cancers. These
ﬁndings indicated that dysregulation of miR-29 expression dis-
rupted tightly regulated RNA networks and that these events con-
tributed to cancer cell development and metastasis. Therefore,
identiﬁcation of miR-29-modulated cancer pathways is important
for the elucidation of molecular mechanisms of human oncogene-
sis and metastasis.
Our present data showed that all members of the miR-29 family
were signiﬁcantly reduced in ccRCC specimens. Moreover, restora-
tion of these miRNAs inhibited cancer cell migration and invasion,
providing insights into the functional roles of all members of the
miR-29 family as tumour suppressors in ccRCC cells.
Tumour-suppressive roles of miR-29s were reported by previous
studies in several cancers [6–8]. These earlier ﬁndings areFig. 4. Effect of si-LOXL2 transfection on RCC cell lines. (A) LOXL2mRNA expression level
used for normalization. (B) LOXL2 protein expression 96 h after transfection with 10 nM
transfection with 10 nM si-LOXL2 was determined with the XTT assay. (D) Cell migration
assay. (E) Cell invasion activity 48 h after transfection with 10 nM si-LOXL2 was determconsistent with our present results. However, the molecular mech-
anisms underlying the dysregulated expression of the miR-29
family in ccRCC cells are still unclear.
Recent in silico analysis of promoter regions of
miR-29b-1/miR-29a showed that two putative E-box sites
(MYC-binding sites), a Gli-binding site and four NF-kB-binding
sites were contained within this region [20]. This report demon-
strated that expression of MYC and inhibition of hedgehog
signalling suppressed the promoter activities of miR-29b-1/miR-29a
in cholangiocarcinoma cells [20]. Other studies showed that
GATA3, a transcription factor, promoted differentiation, sup-
pressed metastasis and altered the tumour microenvironment in
breast cancer by inducing miR-29b expression [21]. Interestingly,
several reports have shown that the c-MYC pathway is activated
in RCC due to the overexpression and ampliﬁcation of the c-MYC
gene [22,23]. Our previous study also showed that c-MYC was
signiﬁcantly upregulated in ccRCC clinical specimens and silencing
of c-MYC inhibited cancer cell proliferation and invasion [24].
These ﬁndings suggested that overexpression of c-MYC modulates
tumour-suppressive miRNAs in ccRCC cells, such as miR-29s.
Moreover, recent data have suggested that TGF-beta inhibited the
expression of miR-29s and promoted the expression of extracellu-
lar matrix (ECM) components [25,26]. It is likely that aberrants were measured by qRT-PCR 72 h after transfection with 10 nM si-LOXL2. GUSB was
si-LOXL2. GAPDH was used for a loading control. (C) Cell proliferation 72 h after
activity 48 h after transfection with 10 nM si-LOXL2 was determined by migration
ined with the invasion assay. **P < 0.0001.
Fig. 5. Expression levels of LOXL2 in RCC clinical specimens. (A) Expression levels of LOXL2 in RCC clinical specimens. GUSB was used for normalization. (B) Correlations
between LOXL2 expression and miR-29 expression were determined in RCC clinical specimens.
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miR-29s expression in ccRCC cells. Detailed examination will be
necessary to better understand these processes.
Recent studies have suggested that cancer cells’ interaction
with their microenvironment can affect the initiation, develop-
ment and metastasis of tumours [27–30]. Overexpression of ECM
components has been observed in several cancers. This aberration
contributes to cancer cell progression by dysregulation of cell
adhesion, polarity and ECM remodelling [31,32]. Our past studies
found thatmiR-29s directly regulated laminin (LAMC2) and integrin
(ITGA6), and thereby activated cancer cell migration and invasion
[6]. Other studies indicated that miR-29s modulated ECM compo-
nents such as collagen, laminin and elastin [18]. Therefore, deeper
understanding of the targeting of ECM component genes by
miR-29s might provide better appreciation of novel pathways and
how their interrelations are involved in cancer metastasis.
To better understand ccRCC oncogenesis and metastasis, we
searched miR-29 target genes and used a combination of gene
expression analysis of miR-29a transfectants and in silico database
analysis. In this way, we identiﬁed LOXL2 as a target gene of
tumour-suppressive miR-29s and validated the direct binding of
this miRNA to the 30-UTR of LOXL2 using luciferase reporter assays.
However, many targets of miR-29s regulation contributing to can-
cer cell migration and invasion are still unclear. In this study, we
listed the putative candidate targets of miR-29s regulation in RCC
cells. Among them, several studies showed that SPARC (osteonec-
tin) was regulated by miR-29s and overexpression of SPARC pro-
moted cancer cell proliferation and invasion [19,33]. Moreover,
recent study indicated that miR-29c might be involved in the reg-
ulation of cell proliferation through targeting RCC2 (Regulator ofChromosome Condensation 2) in gastric carcinoma [34]. These
ﬁndings suggested that miR-29s regulated genes were contributed
to the progression of cancer cells widely.
The lysyl oxidase (LOX) protein family comprises LOX and four
LOX-like proteins (LOXL1-LOXL4). These proteins are copper- and
quinone-dependent amino oxidases [35]. Basically, the function
of the LOX family is covalent crosslinking of collagen and/or elastin
in the ECM [36,37]. Aberrant expression of LOX-family proteins has
been reported in several diseases, including cancers [35–40].
Moreover, increased expression of LOXL2 is correlated with disease
progression, including RCC [35,41]. Previous studies have shown
that LOXL2 is a direct transcriptional target of HIF-1. Moreover,
nuclear LOXL2 interacts with transcription factor SNAIL1 and
represses E-cadherin as well as induces EMT [42,43].
Interestingly, targeting LOXL2 with antibodies inhibited primary
and metastatic xenograft models of cancers via suppression of
SRC/FAK signalling or production of growth factors and cytokines
and TGF-b pathways [44,45]. These ﬁndings suggest that downreg-
ulation of tumour-suppressive miR-29a/b/c and overexpression of
HIF-1 in ccRCC cells promote constitutive activation of
LOXL2-modulating cancer pathways. Therefore, inhibition of
LOXL2-modulation pathways could offer new therapeutic
approaches to ccRCC.
In conclusion, downregulation of miR-29s was frequently
observed in ccRCC clinical specimens. All members of the miR-29
family were shown to function as tumour suppressors in ccRCC
cells. To the best of our knowledge, this is the ﬁrst report demon-
strating that tumour-suppressive miR-29s directly regulate LOXL2
in ccRCC cells. Moreover, LOXL2 was upregulated in ccRCC clinical
specimens and contributed to cancer cell migration and invasion,
Fig. 6. Immunohistochemical staining of LOXL2 in RCC clinical specimens. Differences in LOXL2 expression were observed in cancer lesions and adjacent normal prostate
tissues in the same ﬁelds. Overexpression of LOXL2 was observed in cancer lesions. In contrast, negative staining of LOXL2 in normal tissues (left panel, original magniﬁcation
50, H&E staining; right panel, original magniﬁcation 50, immunohistochemical staining of LOXL2).
2144 R. Nishikawa et al. / FEBS Letters 589 (2015) 2136–2145indicating that it functioned as an oncogene. The identiﬁcation of
novel molecular pathways and targets regulated by the
miR-29s-LOXL2 axis may lead to a better understanding of ccRCC
and the development of new therapeutic strategies to treat this
disease.
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